<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953509</url>
  </required_header>
  <id_info>
    <org_study_id>5F9003</org_study_id>
    <nct_id>NCT02953509</nct_id>
  </id_info>
  <brief_title>Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forty Seven, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Forty Seven, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b/2 trial will evaluate Hu5F9-G4 (magrolimab) in combination with rituximab and
      magrolimab or in combination with R-GemOx. Magrolimab is a monoclonal antibody which is
      designed to block a protein called CD47, which is widely expressed on human cancer cells.
      Blocking CD47 with magrolimab may enable the body's immune system to find and destroy the
      cancer cells. Rituximab is a monoclonal antibody drug that is used for treatment of
      non-Hodgkin's lymphoma and other types of cancer. Gemcitabine and Oxaliplatin are
      chemotherapy commonly used with rituximab in treating NHL.

      The major aims of the trial are: (Phase 1b) to investigate the safety and tolerability of
      sequential dose cohorts and to determine a recommended Phase 2 dose for Hu5F9-G4 in
      combination with rituximab, and (Phase 2) to evaluate the efficacy of Hu5F9-G4 in combination
      with rituximab in patients with indolent lymphoma or diffuse large B-cell lymphoma as
      measured by the overall response rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (Number of participants with a DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Dose-limiting toxicities (DLTs) (Phase 1b only) Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response (defined by the Investigator according to the Lugano classification for lymphomas)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Phase 2: Objective response as defined by the Investigator according to the Lugano classification for lymphomas</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Concentration vs time of magrolimab in combination with rituximab or rituximab +GemOx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA to magrolimab</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Presence or absence of antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response; Progression Free Survival, Overall Survival, Time to Progression</measure>
    <time_frame>up to 40 months</time_frame>
    <description>Response data over time as defined by the investigator according to Lugano and LYRIC criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Rate of Response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed Investigator according to LYRIC criteria for lymphomas</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">422</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Indolent Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1b dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 1b, patients with B-cell non-Hodgkin's lymphoma will receive escalating doses of Hu5F9-G4 in combination with ritixumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 indolent lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2, patients with indolent lymphoma will receive Hu5F9-G4 in combination with ritixumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 diffuse large B-cell lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 2, patients with diffuse large B-cell lymphoma will receive Hu5F9-G4 in combination with ritixumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b diffuse large B-cell lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Phase 1b, patients with diffuse large B-cell lymphoma will receive escalating doses of magrolimab in combination with ritixumab + gemcitabine and oxaliplatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hu5F9-G4</intervention_name>
    <arm_group_label>Phase 1b diffuse large B-cell lymphoma</arm_group_label>
    <arm_group_label>Phase 1b dose escalation</arm_group_label>
    <arm_group_label>Phase 2 diffuse large B-cell lymphoma</arm_group_label>
    <arm_group_label>Phase 2 indolent lymphoma</arm_group_label>
    <other_name>magrolimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Phase 1b diffuse large B-cell lymphoma</arm_group_label>
    <arm_group_label>Phase 1b dose escalation</arm_group_label>
    <arm_group_label>Phase 2 diffuse large B-cell lymphoma</arm_group_label>
    <arm_group_label>Phase 2 indolent lymphoma</arm_group_label>
    <other_name>RITUXAN®</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <arm_group_label>Phase 1b diffuse large B-cell lymphoma</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Phase 1b diffuse large B-cell lymphoma</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phase 1b only: B-cell non-Hodgkin's lymphoma (NHL), relapsed or refractory to standard
             approved therapies

          -  DLBCL Phase 2 cohort: De novo or transformed diffuse large B-cell lymphoma (DLBCL)
             expressing CD 20, relapsed or refractory to at least 2 prior lines treatment
             containing anti-CD20 therapy

          -  Indolent lymphoma Phase 2 cohort: Marginal zone or follicular lymphoma, relapsed or
             refractory to standard approved therapies

          -  DLBCL chemotherapy combination cohort: De novo or transformed diffuse large B-cell
             lymphoma (DLBCL), relapsed or refractory to 1-3 prior lines of treatment

          -  Adequate performance status and hematological, liver and kidney functions

          -  Willing to consent to 1 mandatory pre-treatment and 1 on-treatment tumor biopsy

        Exclusion Criteria:

          -  Active brain metastases

          -  Prior allogeneic hematopoietic cell transplantation

          -  Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents

          -  Second malignancy within the last 3 years

          -  Known active or chronic hepatitis B or C infection or HIV

          -  Pregnancy or active breastfeeding

          -  Prior CAR-T therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mwe Mwe Chao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Forty Seven, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mwe Mwe Chao, MD</last_name>
    <phone>650-352-4133</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama At Birmingham (Uab) Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Caterinicchia, RN,BSN</last_name>
      <phone>205-934-5367</phone>
      <email>val7@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Amitkkumar Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Popplewell, MD</last_name>
      <phone>626-256-4673</phone>
      <email>lpopplewell@coh.org</email>
    </contact>
    <investigator>
      <last_name>Leslie Popplewell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaitasi Majmudar</last_name>
      <phone>650-736-0959</phone>
      <email>majmudar@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjana Advani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Wall, RN</last_name>
      <phone>706-721-4430</phone>
      <email>swall@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Locke Bryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coleen McKeown</last_name>
      <phone>773-702-9791</phone>
      <email>cmckeown@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Sonali Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>240-760-6050</phone>
      <email>NCIMO_Referrals@mail.nih.gov</email>
    </contact>
    <investigator>
      <last_name>Mark Roschewski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blood Cancer Program</last_name>
    </contact>
    <contact_backup>
      <last_name>Susan Bright, RRN</last_name>
      <email>sbright@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jon Arnason, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillian Foreman</last_name>
      <phone>617-582-8713</phone>
      <email>JillianM_Foreman@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Ann LaCasce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U-M Cancer Answerline</last_name>
      <phone>800-865-1125</phone>
      <email>CancerAnswerLine@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Tycel Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Maakaron, MD</last_name>
      <phone>612-624-5109</phone>
      <email>krblomqu@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Maakaron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Sprengel</last_name>
      <phone>314-747-7399</phone>
      <email>hsprengel@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Bartlett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Healthcare Systems- Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Anderson</last_name>
      <phone>980-442-2365</phone>
      <email>angela.p.anderson@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Nilanjan Ghosh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stevenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Caldwell, LPN</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48171</phone_ext>
      <email>Christina-Caldwell@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Asch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Delp, RN</last_name>
      <phone>215-220-9632</phone>
      <email>Grace.Delp@Pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Sunita Nasta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Flinn, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Christy Riggins, MA</last_name>
      <email>CANN.ResearchReferrals@scresearch.net</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Flinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-792-2860</phone>
      <email>jwestin@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jason Westin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxforshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesaria Ehibhatiomhan, RN</last_name>
      <email>orh-tr.earlyphasenurses@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Graham Collins, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <keyword>diffuse large B-cell lymphoma</keyword>
  <keyword>indolent lymphoma</keyword>
  <keyword>Hu5F9-G4</keyword>
  <keyword>CD47</keyword>
  <keyword>magrolimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Hu5F9-G4</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

